



[Redacted]

Dr. [Redacted]

This letter acknowledges the receipt and review of your new IBC registration identified below. Your protocol is categorized as being regulated by the *NIH Guidelines* on recombinant activity and subject to IBC review and approval. The IBC has **approved** your registration.

Title of IBC Protocol:  
IBC Protocol No.:  
Location of Research Activity:  
NIH Classification:  
Biosafety Containment and RG:  
**Renewal Deadline:**

[Redacted]

IBC approval is applicable for no more than **three (3) years** from the date of the most recent full protocol review and approval and is subject to a mandatory annual review inspection. Renewals and amendments require submission of an IBC registration and IBC review.

Adherence to:

1. Biosafety Level 2 Practices, CDC-NIH *Biosafety in Microbiological and Biomedical Laboratories* (BMBL 5th edition 2009)
2. Appendix G-11-8 Biosafety Level 2 Practices from the *NIH Guidelines for Research Involving Recombinant DNA Molecules and Synthetic Nucleic Acid Molecules*
3. UH IBC Policy Section IX. Principal Investigator Responsibilities January 2020

[Redacted Signature]

Chair, Institutional Biosafety committee

c: Victoria Rivera, Director, Office of Research Compliance  
Norman Magno, Manager, Biosafety Program, Office of Research Compliance